ADAP Advocacy Report Highlights Hospital CEO Compensation Concerns in 340B Drug Pricing Program
TL;DR
ADAP Advocacy's report reveals how hospital CEOs gain unfair financial advantages by diverting 340B program funds meant for patient care into excessive executive compensation packages.
ADAP Advocacy published infographics showing how the 340B Drug Pricing Program's $66 billion in manufacturer rebates are systematically redirected from patient services to fund hospital CEO compensation packages.
ADAP Advocacy's findings expose how excessive hospital CEO pay compromises the 340B program's mission to provide healthcare access for poor patients and vulnerable communities.
ADAP Advocacy's infographics reveal that hospital CEO compensation grew exponentially after hospitals became eligible for the 340B program originally designed to help poor patients.
Found this article helpful?
Share it with your network and spread the knowledge!
ADAP Advocacy has released a two-part infographic series examining executive compensation practices among hospital CEOs participating in the 340B Drug Pricing Program. The organization's 340B Project documents how manufacturer rebates intended to support healthcare access for low-income patients are instead funding substantial compensation packages for hospital executives.
The '340B Too Big to Fail – Executive Compensation – Part 1' infographic focuses on the significant pay gap between hospital CEOs and frontline nurses, while emphasizing that the 340B Drug Pricing Program was originally designed to help poor patients access essential healthcare services. Despite the program's growth to $66 billion in scale, ADAP Advocacy's research indicates these funds are being diverted to support excessive executive compensation rather than their intended purpose of patient care.
The second infographic, '340B Too Big to Fail – Executive Compensation – Part 2,' demonstrates how CEO compensation has increased exponentially after hospitals became eligible to participate in the 340B Program. This trend raises questions about whether the program is achieving its original mission or has become a source of revenue that benefits hospital administration rather than patients in need.
These findings are part of ADAP Advocacy's broader national advocacy campaign questioning whether the 340B Drug Pricing Program has become 'too big to fail.' The organization emphasizes that the program was not designed to enrich healthcare executives but rather to ensure vulnerable populations can access necessary medications and healthcare services.
The complete two-part infographic series is available for download at https://www.adapadvocacy.org/publications.html#i. This research comes at a critical time as policymakers and healthcare advocates examine the effectiveness and proper administration of the 340B Program, which plays a vital role in supporting safety-net healthcare providers and the patients they serve.
Curated from 24-7 Press Release
